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Abstract 
BACKGROUND: Cardiovascular disease (CVD) is the primary cause of mortality in the world and 
Iran. The aim of this study was to determine the prognostic factors of short-term survival from 
acute myocardial infarction (AMI) in early and late patients in the Najafabad and Isfahan 
County, Iran. 
METHODS: This hospital-based cohort study was conducted using the hospital registry of  
1999-2009 in Iran. All patients (n = 14426) with an AMI referred to hospitals of Isfahan and 
Najafabad were investigated. To determine prognostic factors of short-term (28-days) survival 
in early and late patients, unadjusted and adjusted hazard ratio (HR) was calculated using 
univariate and multivariate Cox regression. 
RESULTS: The short-term (28-day) survival rate of early and late patients was 96.64% and 89.42% 
(P < 0.001), respectively. In 80% of early and 79.3% of late patients, mortality occurred during the 
first 7 days of disease occurrence. HR of death was higher in women in the two groups; it was 1.97 
in early patients was (CI95%: 1.32-2.92) and 1.35 in late patients (CI95%: 1.19-1.53) compared to 
men. HR of death had a rising trend with the increasing of age in the two groups. 
CONCLUSION: Short-term survival rate was higher in early patients than in late patients. In 
addition, case fatality rate (CFR) of AMI in women was higher than in men. In both groups, sex, 
age, an atomic location of myocardial infarction based on the International Classification of 
Disease, Revision 10 (ICD10), cardiac enzymes, and clinical symptoms were significant 
predictors of survival in early and late patients following AMI. 
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Introduction 
Cardiovascular disease (CVD) is the most important 
reason of death in residents of Iran.1 Every month 
around 11500 decease owing to coronary heart disease 
happens in Iran, about 50% of this deaths occurs as a 
result of acute myocardial infarction (AMI).2 This 
disease is the major cause of disability, morbidity, and 
mortality in Iran residents.3-5 Age is one of the 
important factors that have a massive influence on 
decease after heart attack so that older individuals are 
at bigger hazard of mortality from AMI.  
In several studies that conducted around the 
word and detected that the mean age of patients 
who deceased in 28 days afterward the incidence of 
AMI and patients who deceased beforehand getting 
hospital, respectively, in average were 10 and 7 years 
older than survived patients.6,7 Clearly, the 
possibility of decease from AMI was higher in 
elderly. Moreover, albeit only about 10% of the 
entire patients with AMI are < 45 years old.6,7 AMI 
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is a common cause of disability and mortality in a 
lot of countries and causes additional disadvantages, 
especially when it occurs in early patients. In studies 
that have been conducted in different parts of the 
world, factors such as age, sex, type of AMI, 
electrokardiogram (EKG), symptom, cardiac 
enzymes (lactate dehydrogenase, creatine kinase, 
and troponin), hypertension, previous MI, diabetes 
mellitus (DM), hyperlipidemia, season of disease 
event, and smoking introduced as the predictor of 
death from AMI.8-10 
Therefore, identifying prognostic factors of 
mortality in patients could have an important effect 
in decreasing deaths from the disease,11-13 especially 
in countries such Iran that dispersed information has 
about the factors affecting the survival from AMI, 
particularly in early patients that this information is 
little or does not be existent. Therefore, the aims of 
this study are determent prognostic factors of 28-day 
survival rate after AMI in teen year’s period in early 
(younger) and late (older) patients in Isfahan and 
Najafabad County, Iran. 
Materials and Methods 
This study is a hospital-based cohort study that 
implemented to determent predictive factors of  
28-day survival rate from AMI in 10 year’s period in 
Isfahan and Najafabad. The population entered in the 
study involved of all patients (census) that diagnosis 
with first AMI for the period of 1999-2009 in all 
infirmary and hospitals in Isfahan and Najafabad. All 
patients examined afterward admittance to hospitals, 
then patients by AMI related to unalike event locations 
allocated a specific code pursuant to International 
Classification of Diseases-version 10 (ICD-10) based 
on the final diagnosis of hospital cardiologist.  
Trained nurses, who used special questioner for 
gathering evidence about the patients with an 
interview with patients or check the hospital records, 
gathered basic information related to demographic 
and clinical and laboratory characteristics of patients 
and then all documents collected in the Isfahan 
Cardiovascular Research Center. 
By definition of MONICA and the World 
Health Organization (WHO) protocol, AMI as a 
28-day repeated attack, and separate attacks not 
considered according to this definition, but in fact 
related the first AMI; however, following the 
primary night of the 27th day after the first attack, it 
is considered as a new attack. It should be 
mentioned patients who died along the first 28 days 
are considered as death due to first AMI.14 Patients 
are divided into two categories: (1) Early patients 
group (male with age 50 years and below and female 
with 55 years and below) and (2) late patients group 
(male with 51 years and older and female with 56 
years and older). 
After gathering basic information of the patients, 
their survival or deaths during days after the AMI 
examined. For discharged patients, follow-up was first 
executed by telephone, but when he did not answer 
the phone 3 times, we went to the patient’s homes. 
When previous trying to getting information about 
survival rate failed, using the National Organization 
for Civil Registration and Isfahan Cemetery, we tried 
to find out the cause of death if the patient had died; 
and precise date and place of the burial.  
This study encompassed merely patients who 
were resident in Isfahan and Najafabad with 
primary AMI. Overall, 16259 patients (12046 male 
and 4213 female) with primary AMI, that 
inhabitants in Isfahan and Najafabad entered in the 
study, 997 patients (632 male and 365 female) 
omitted because their AMI kind undetermined 
according to the ICD-10. In addition, 152 patient 
(107 male and 45 female) exclude from the study 
because they were died along the 28 days after the 
first attack without mention any CVD due to 
accident, suicide, homicide, chronic obstructive 
pulmonary disease (COPD), types of cancer, 
cirrhosis, rheumatic heart disease, atherosclerosis, or 
vascular disease; and 438 patients (305 men and 133 
female) omitted because outcome of disease was 
unknown. Furthermore, 145 patients (96 men and 
49 female) excluded from the study because the 
unknown exact date of the occurrence or death 
from the disease and the 28-day duration after the 
attack could not calculate in these cases.14 
Moreover, 101 patients (56 men and 45 female) 
excluded because symptom or cardiac enzymes 
were not recorded. Therefore, 14426 patients, 
10850 (75.2%) men and 3576 (24.8%) female, 
stayed in the study and 11.27% of patient censored. 
Detailed description of the material and methods 
utilized in this scheme provided in previous 
reports.10,12,13,15-17 
Variables that considered in the study include 
age that divide in six subgroup (39 years and lower, 
40-49, 50-59, 60-69, 70-79, and 80 and older); 
streptokinase use (receiving or not receiving); kind 
of AMI-based ICD-10 that include six categories: 
(I21.0) Acute transmural MI of anterior wall, 
(I21.1) acute transmural MI of inferior wall, (I21.2) 
acute transmural MI of other sites, (I21.3) acute 
transmural MI of unspecified site, (I21.4) acute 
subendocardial MI, (I21.9) AMI; unspecified, the 
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first center that patient referred for get medical 
care (non-specialized hospitals, specialized 
hospital, unknown, health network, or clinic); 
symptoms (typical, atypical, others, not clear); 
cardiac enzymes (atypical, typical, others, not 
clear); and hospital status (privative hospitals and 
academic hospitals).  
In this study, continuous variables presented as 
mean ± standard deviation (SD). To compare 
average age in two genders, we use of the 
independent t-test. Time-dependent event (survival) 
rates were estimated by Kaplan–Meier method, and 
P values were determined by use of log-rank 
statistics. The assumption of proportional hazards 
assessed by the log-minus-log diagram. 
Furthermore, to calculate the hazard ratio (HR) of 
death in 28 days of onset AMI, multivariate cox 
regression was used for calculation adjusted HR and 
category that have the lowest mortality, considered 
as the reference group. In calculate of adjusted HR 
every variable adjusted for other variables. Statistical 
significance assumed in conditions that P < 0.050. 
All testified P values are two-sided. Statistical 
analyzes performed with using SPSS software 
(version 15, SPSS Inc., Chicago, IL, USA). 
Results 
In overall, 14426 patients with AMI throughout the 
study period admitted in Isfahan and Najafabad 
hospitals. From this patients, 10850 (75.2%) was male, 
and 3576 (24.8%) was female. Sex ratio (male/female) 
was 3.03. In this study, the mean age of the patients in 
the disease occurrence time was (14426 patients) 60.83 
± 12.22, in male (10850 patients) 58.96 ± 11.92, and in 
female (3576 patients) 66.50 ± 11.34 and that different 
between average age in two genders was statically 
significant (P < 0.001).  
Short-term (28-day) survival rate in study period 
was 91.5% (93.0% in male and 86.8% in female)  
(P < 0.001). Short-term (28-day) survival rate in 
early patients was 96.6% and in late patients was 
89.4% (P < 0.001), in early patients was 94.2 and 
97.4% (P = 0.556) and in late patients 85.4 and 
91.8% (P < 0.001), respectively, for female and 
male. Short-term (28-day) survival rates of the two 
groups (early and late patients) for each of the 
variables are presented in tables 1-3. 
In patients with AMI, the highest probability of 
mortality was during the first 7 days after the 
disease occurrence. Therefore, that 80.0% of deaths 
in early patients occurs during the 1st week after the 
even (39.3% in the day of incidence disease and 
40.7% in 1-7 days after the disease occurrence) and 
in late patients 79.3% (44.3% in the day of 
incidence disease and 35.0% in 1-7 days after the 
disease occurrence) (Table 1).  
HR of decease in two genders, in female was 
higher than male. So, in early patients was  
HR = 1.97; confidence interval (CI) 95%: 1.32-2.92 
and in late patients was HR = 1.35; CI 95%:  
1.19-1.53. In two groups, HR of death increases 
with increasing age; so that, in the early patients in 
age group 40-44 years was HR = 1.46; CI 95%:  
0.56-3.79, 45-49 years was HR = 2.71; CI 95%: 
1.14-6.44 and in age group 50-55 was HR = 3.44; 
CI 95%: 1.49-7.92 compared by 39 years and lower 
age group that HR with 95% CI only for age group 
40-44 years was not statistically significant. 
 
Table 1. Patient’s demographic and 28 days case fatality rate 
Variables Early patients Late patients Female < 55 Male < 50 Total Female > 55 Male > 50 Total 
Total [n (%)] 586 (14.1) 3571 (85.9) 4157 (100) 2990 (29.1) 7279 (70.9) 10269 (100) 
Sex ratio (male/female) 6.09 - 2.43 - 
Age (year) (mean ± SD) 48.5 ± 5.4 47.2 ± 6.2 47.38 ± 6.11 70.02 ± 8.5 64.73 ± 9.58 66.27 ± 9.59 
Survival status       
Dead 34 106 140 437 650 1087 
Alive 552 3465 4017 2553 6629 9182 
CFR (%) 5.8 2.96 3.4 14.6 8.9 10.6 
Survival rate (%) 94.2 97.4 96.6 85.4 91.1 89.4 
Means for survival time (day) 26.06 27.31 27.21 24.47 25.93 25.5 
CI 95% 26.12-27.6 27.18-27.45 27.08-27.34 24.15-24.78 25.77-25.65 25.36-25.65 
Day of death after hospitalization and survival rate [n (%)]     
Day 0  11 (32.4) 44 (41.9) 55 (39.6) 214 (49.0) 268 (41.2) 482 (44.3) 
Days 1-7 20 (58.8) 37 (35.2) 57 (41.0) 146 (33.4) 234 (36.0) 380 (35.0) 
Days 8-14 1 (2.9) 13 (12.4) 14 (10.1) 48 (11.0) 78 (12.0) 126 (11.6) 
Days 15-21 2 (5.9) 9 (8.6) 11 (7.5) 23 (5.3) 49 (7.5) 72 (6.6) 
Days 22-28 0 (0) 3 (1.9) 3 (1.8) 6 (1.4) 21 (3.2) 27 (2.5) 
SD: Standard deviation; CI: Confidence interval; CFR: Case fatality rate 
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In late patients, in age group 60-69 years was  
HR = 2.03; CI 95%: 1.64-2.5, 70-79 years was  
HR = 2.88; CI 95%: 2.35-3.53, and in 80 years and 
older was HR = 3.85; CI 95%: 3.06-4.84 compared 
by 50-59 years age group. 
In both groups, HR of death in patients with 
acute sub-endocardial MI was lowest and acute 
transmural MI of unspecified site was highest; so, in 
early patients was HR = 22.42; CI 95%: 4.24-118.37 
and in late patients was HR = 10.52; CI 95%:  
6.41-17.28 (Tables 2 and 3). 
Receiving streptokinase therapy in predicting 
survival in early and late patients is not a 
determining factor so that the HR of occurrence of 
death in patients who have not received the drug, 
respectively, in early and late patients were  
HR = 1.01; CI 95%: 0.71-1.46 and HR = 1.09; CI 
95%: 0.95-1.24 that is not statistically significant. 
HR for other variables presented in tables 2 and 3. 
Discussion 
In this study, 28-day survival rate was 91.5%, in 
early patients 96.6% and in late patients 89.4%, and 
the highest probability of mortality (80.0%) was 
during the first 7 days after the disease occurrence. 
HR of demise in female was higher than male and 
increases with increasing age; acute sub-endocardial 
MI has lowest and acute transmural MI of the 
unspecified site have highest HR for mortality in 
first 28 days of disease start. 
From 14426 patients with AMI that entered in 
the study, 10850 (75.2%) were male and sex ratio 
(male/female) was 3.03, parallel results in this 
context found in other studies.18,19 The average age 
of patients in disease occurrence time in female was 
7/5 years upper than male and these results also 
been observed in other studies.9,20,21 Short-term (28-
day) survival rate in the entire patients in the study 
was 91.5% - for males 93.0% and females 86.8%; 
and in early patients were 96.6% and in late patients 
were 89.4%. In fact, the risk ratio of death in 28 
days after the onset of disease in late patients is 3.2 
times higher than early patients. In a study that 
conducted in Yazd, Iran, by Soltani et al.22 on 815 
patients with AMI, patients divided into two age 
groups: ≤ 45 years (young) and > 45 years (old). In 
two genders, young patients had less in-hospital 
mortality than old patients, so in male was 1.2 vs. 
9.1% (P = 0.005) and in female was 10.0 vs. 19.9% 
(P = 0.300). Similar results observed in other 
studies.7,12 Therefore, age has an important role in 
determining survival rate in the patients with AMI. 
So, in both group (early and late patients) with 
increasing age-adjusted HR of mortality increased 
compared to baseline group, in a study that 
conducted by Stevenson et al.,23 age of patients was 
important determent factor in 6-month survival rate 
in patients with AMI. However, this result that the 
risk of death increased with rising age has been 
observed in other studies.24,25 
HR of death in 28 days after the onset of disease 
in female are 2.23 and 1.78 time higher than male, 
respectively, for early and late disease type. Perhaps, 
higher death in the first 28 days after the happening 
of AMI in female, resulting from the higher age, 
higher prevalence of diabetes, higher ratio of female 
with poor prognosis who survived to hospital, and 
also, because aging is reduced pain perception and 
response to pain.13,20,26-32 Nevertheless, in this study 
due to lack of availability of data on the above 
variables, we cannot analysis effect of this variable 
on survival based on gender.  
According to ICD-10, MI divided into six 
groups. In this study, for determent the HR of 
mortality from AMI considered a group of patients 
who had the higher survival rate as a base group 
(acute subendocardial MI), HR of other groups 
determined. In two groups (early and late patients), 
acute transmural MI of the unspecified site has 
highest HR compare basic group and after, AMI, 
unspecified (Tables 1 and 2). Furthermore, in both 
groups (early and late patients), acute transmural MI 
of the anterior wall has higher HR compare acute 
transmural MI of inferior wall. Thus, in this study, 
the anatomic location of MI was a significant 
predictor of survival in early and late patients. In a 
number of studies, the prognosis of MI-based 
location was different so that the anterior surface 
infarction has a worse prognosis compared to 
inferior level.9,24,33 
However, according to the method of data 
analysis in this study, we adjusted difference in 
various types of MI, and after calculated adjusted 
HR. Therefore, difference between adjusted HR for 
mortality from AMI according to ICD-10 cannot 
cause by a variety of factors such as: gender, age, 
kind of hospital, receive or did not receive 
streptokinase, and also difference in symptoms 
(typical, atypical, others, and miss), cardiac enzymes 
(atypical, typical, other and not clear), and EKG 
(definite, probable, ischemic, other, impossible 
coding, miss). 
In England, overall 82.0% of hospitals used 
streptokinase for treatment of patients that for the 
first time suffering from AMI and have medical 
conditions of receiving this drug.34 
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Table 2. Predictive factors in 28-day survival rate in early patients with acute myocardial infarction in Isfahan 
Variables 
The number of patients 
alive at 28-day after the 
first MI (%) 
The number of deaths 
occurred in the first 
28-day after MI 
Survival rates at 28-day 
after the occurrence of 
the disease (%) 
HR for death in the first 28-
day after a first MI with 
95% CI (unadjusted) 
HR for death in the first 
28-day after a first MI 
with 95% CI (adjusted)* 
Sex      
Male 3571 106 97.0 - - 
Female 586 34 94.2 1.98 (1.34-2.91) 1.97 (1.32-2.92) 
Age group (year)      
39 year and lower 440 6 98.6 - - 
40-44 739 15 98.0 1.49 (0.57-3.84) 1.46 (0.56-3.79) 
45-49 1124 38 96.6 2.49 (1.05-3.84) 2.71 (1.14-6.44) 
50-55 1854 81 95.6 3.24 (1.41-7.42) 3.43 (1.49-7.92) 
Streptokinase      
Receiving 2509 77 96.9 - - 
Not receiving 1648 63 96.2 1.24 (0.89-1.74) 1.01 (0.71-1.46) 
ICD-10      
Acute subendocardial MI 331 2 99.4 - - 
Acute transmural MI of other sites 103 5 95.1 8.18 (1.58-42.20) 8.70 (1.66-45.63) 
Acute transmural MI of inferior wall 1334 25 98.1 3.12 (0.73-13.17) 3.38 (0.77-14.75) 
Acute transmural MI of anterior wall 1420 39 97.3 4.59 (1.10-19.00) 4.92 (1.15-21.06) 
AMI, unspecified 932 64 93.1 11.70 (2.86-47.80) 11.62 (2.79-48.33) 
Acute transmural MI of unspecified site 37 5 86.5 24.18 (4.69-124.66) 22.42 (4.24-118.37) 
Symptoms      
Typical 3542 112 96.8 - - 
Atypical 477 17 96.4 1.12 (0.67-1.88) 0.99 (0.59-1.67) 
Others 128 10 92.2 2.52 (1.32-4.81) 2.11 (1.08-4.10) 
Miss 10 1 90.0 3.35 (0.46-24.03) 0.54 (0.06-4.28) 
Cardiac enzymes      
Others 384 9 97.7 - - 
Typical 3189 93 97.1 1.24 (0.62-2.47) 1.40 (0.69-2.80) 
Atypical 478 20 95.8 1.80 (0.82-3.96) 1.93 (0.87-4.26) 
Not clear 106 18 83.0 7.96 (3.57-17.73) 7.27 (3.22-16.4) 
EKG      
Ischemic 675 16 97.6 - - 
Probable 80 7 91.2 3.79 (1.55-9.21) 3.37 (1.36-8.36) 
Other 39 1 97.4 1.07 (0.14-8.07) 1.03 (0.13-7.90) 
Definite 3268 102 96.9 1.32 (0.78-2.23) 1.60 (0.91-2.81) 
Impossible coding 50 10 80.0 9.59 (4.35-21.13) 6.73 (2.96-15.30) 
Miss 45 4 91.1 3.90 (1.30-11.67) 5.57 (1.81-17.10) 
*Every variable adjusted for other variables; ICD: International Classification of Disease; AMI: Acute myocardial infarction; EKG: Electrokardiogram; HR: Hazard ratio; CI: Confidence interval 
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Table 3. Predictive factors in 28-day survival rate in late patients with acute myocardial infarction in Isfahan 
Variables 
The number of patients 
alive at 28-day after the 
first MI (%) 
The number of deaths 
occurred in the first 
28-day after MI 
Survival rates at 28-day 
after the occurrence of 
the disease (%) 
HR for death in the first 28-
day after a first MI with 
95% CI (unadjusted) 
HR for death in the first 
28-day after a first MI 
with 95% CI (adjusted)* 
Sex      
Male 7279 650 91.1 - - 
Female 2990 437 85.4 1.68 (1.49-1.90) 1.35 (1.19-1.53) 
Age group (year)      
50-59 2893 126 95.6 - - 
60-69 3381 311 90.8 2.16 (1.76-2.66) 2.03 (1.64-2.50) 
70-79 3038 447 85.3 3.54 (2.91-4.32) 2.88 (2.35-3.53) 
80 and higher 957 203 78.8 5.26 (4.21-6.58) 3.85 (3.06-4.84) 
Streptokinase      
Receiving 5118 497 90.3 - - 
Not receiving 5151 590 88.5 1.18 (1.05-1.33) 1.09 (0.95-1.24) 
ICD-10      
Acute subendocardial MI 979 26 97.3 - - 
Acute transmural MI of other sites 263 14 94.7 2.04 (1.06-3.92) 1.67 (0.87-3.20) 
Acute transmural MI of inferior wall 2839 175 93.8 2.36 (1.56-3.56) 1.73 (1.13-2.64) 
Acute transmural MI of anterior wall 3391 317 90.7 3.63 (2.43-5.41) 2.81 (1.86-4.23) 
AMI, unspecified 2674 513 80.8 7.86 (5.30-11.65) 5.40 (3.62-5.07) 
Acute transmural MI of unspecified site 123 42 65.9 15.24 (9.34-24.86) 10.52 (6.41-17.28) 
Symptoms      
Typical 8461 829 90.2 - - 
Atypical 1202 124 89.7 1.05 (0.87-1.27) 0.96 (0.79-1.16) 
Others 555 123 77.8 2.41 (1.99-2.91) 1.52 (1.24-1.85) 
Miss 51 11 78.4 2.36 (1.30-4.28) 1.61 (0.88-2.93) 
Cardiac enzymes      
Atypical 1344 104 92.3 - - 
Typical 7602 726 90.4 1.23 (1.08-1.52) 1.29 (1.05-1.59) 
Other 896 77 91.4 1.12 (0.83-1.50) 1.19 (0.88-1.60) 
Not clear 427 180 57.8 7.03 (5.52-8.95) 5.17 (4.04-6.63) 
EKG      
Other 49 2 95.9 - - 
Probable 187 26 86.1 3.57 (0.84-15.05) 2.27 (0.53-9.60) 
Ischemic 1721 110 93.6 1.56 (0.38-6.33) 1.06 (0.26-4.32) 
Definite 7954 859 89.2 2.69 (0.67-10.79) 2.07 (0.51-8.36) 
Impossible coding 208 50 76.0 6.46 (1.57-26.58) 2.64 (0.64-10.89) 
Miss 150 40 73.3 7.58 (1.83-31.30) 3.08 (0.74-12.83) 
*Every variable adjusted for other variables; ICD: International Classification of Disease; AMI: Acute myocardial infarction; EKG: Electrokardiogram; HR: Hazard ratio; CI: Confidence interval 
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In this study, although short-term (28-day) 
survival rate in early and late patients that receive 
streptokinase are higher from not receiving group 
but adjusted HR for death in not receiving group 
and are not significant. So that, patients who not 
received treatment, compared to the group 
receiving the drug, respectively, in early and late 
patients have adjusted HR = 1.01; CI 95%:  
0.71-1.46 and HR = 1.09; CI 95%: 0.95-1.24. Thus, 
it can be seen that in both groups, receive and not 
receiving streptokinase are not significant 
determinate of short-term (28-day) survival in AMI 
patients. This article extracted from a research 
project with code 84130 in 2011 in Isfahan 
Cardiovascular Research Institute. 
Limitation 
A trouble of this study is a shortage of complete, 
community-based case ascertainment, which 
contains through protocols for discovery 
community fatal and non-fatal MI patients who not 
admitted to the hospitals. Most important is the 
shortage of information about out of hospital fatal 
cases such as MI cases that receive care managed at 
the house or in health centers. This figure is 
unimportant because in Iran care system MI events 
consider as emergency condition and all hospitals 
must admit such patients irrespective of their 
insurance position. In the study in Danish 
MONICA population, this patient contains < 1% 
of total MI cases. Therefore, the missing these 
patients would not lead to severe changes in case 
fatality rate (CFR). 
Conclusion 
The short-term survival rate in early patients is 
higher than late. In addition, CFR from AMI in 
female is higher than male. The highest probability 
of mortality (80.0% in early and 79.3% in late 
patients) was during the first 7 days after the disease 
occurrence. In both groups (early and late patients): 
sex, age, anatomic location of MI-based ICD-10, 
cardiac enzymes, and clinical symptoms are 
significant prognostic factors of survival in patients 
following AMI. 
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